TMEM199-CDG, also known as congenital disorder of glycosylation type IIp, is a very rare condition that belongs to a group of disorders affecting how certain proteins are built and modified in the body. This condition has been referred to by many names including CDG syndrome type IIp, CDG-IIp, carbohydrate deficient glycoprotein syndrome type IIp, and congenital disorder of glycosylation, type IIp. These different names highlight the complexity and evolving nature of the understanding of this disorder. Because detailed information is not widely available, much about TMEM199-CDG remains uncertain. Research has linked this condition to changes in the VMA12 gene, but many details such as the full range of symptoms, the typical progression, and the impact on daily life are still under investigation. More work is needed to clarify the underlying biology and improve the overall understanding of this rare disorder.

Information about symptoms is currently limited for this condition. The range and severity of symptoms in people with TMEM199-CDG are not well defined in the available sources, and further study is needed to provide a clearer picture.

TMEM199-CDG is linked to genetic changes in the VMA12 gene. Changes in this gene are thought to affect normal cellular processes that help in the proper modification and function of proteins. While the detailed role of the VMA12 gene in the development of this condition is not fully described in current resources, its involvement underscores the genetic nature of TMEM199-CDG. Further research is needed to fully understand how these genetic alterations lead to the clinical features of the disorder. Associated genes include VMA12.